Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

Agenus Inc. will release its first quarter 2024 financial results on May 7, 2024. The company is a leader in developing novel immunological agents to treat various cancers. Agenus executives will discuss the results and provide a corporate update during a conference call and webcast at 8:30 a.m. ET.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update.

Conference Call:

To access dial-in numbers, please register here.

Conference ID: 73242

A live webcast and replay of the conference call will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/928123199.

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding a its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2022, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240423870121/en/

Investors

917-362-1370

investor@agenusbio.com



Media

917-362-1370

communications@agenusbio.com

Source: Agenus Inc.

FAQ

When will Agenus release its first quarter 2024 financial results?

Agenus will release its first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.

What does Agenus specialize in developing?

Agenus specializes in developing novel immunological agents to treat various cancers.

When will the conference call and webcast to discuss the financial results take place?

The conference call and webcast to discuss the financial results will take place at 8:30 a.m. ET on the morning of May 7, 2024.

Where can one access the live webcast and replay of the conference call?

The live webcast and replay of the conference call can be accessed on Agenus' website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/928123199.